MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

BACKGROUND: Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma. In glioblastoma, promoter methylation of the counteracting DNA repair enzyme O(6)-methylguanine-DNA-methyltransferase (MGMT) correlates with survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassel, J C, Sucker, A, Edler, L, Kurzen, H, Moll, I, Stresemann, C, Spieth, K, Mauch, C, Rass, K, Dummer, R, Schadendorf, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966614/
https://www.ncbi.nlm.nih.gov/pubmed/20736948
http://dx.doi.org/10.1038/sj.bjc.6605796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966614/
https://www.ncbi.nlm.nih.gov/pubmed/20736948
http://dx.doi.org/10.1038/sj.bjc.6605796

Ejemplares similares